Evidence map›Paper›PMID 38593276›Full record

ArticleThe Kaohsiung journal of medical sciences2024

NTRK3 exhibits a pro-oncogenic function in upper tract urothelial carcinomas.

Lee-Moay Lim, Yi-Chen Lee, Ting-Wei Lin, Zi-Xuan Hong, Wei-Chi Hsu, Hung-Lung Ke, Daw-Yang Hwang, Wen-Yu Chung, Wei-Ming Li, Hui-Hui Lin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Lee-Moay LimGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yi-Chen LeeGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0002-4889-095X
Ting-Wei LinGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Zi-Xuan HongGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Wei-Chi HsuDepartment of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hung-Lung KeGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0002-4208-3858
Daw-Yang HwangNational Institute of Cancer Research, National Health Research Institute, Tainan, Taiwan.
Wen-Yu ChungDepartment of Computer Science and Information Engineering, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan.
Wei-Ming LiDepartment of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hui-Hui LinDepartment of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hung-Tien KuoDivision of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
A-Mei HuangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0003-3723-0443
Kaohsiung Medical University · TWNational Health Research Institutes · TWUniversity of Science and Technology · YE

Funding

Kaohsiung Medical University KMU-M112020Kaohsiung Medical University KMU-M112020 to A.M.H.Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH110-0R18Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH111-1R13Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH111-1R13 to L.M.L.National Science and Technology Council MOST 109-2635-B-037-009National Science and Technology Council MOST 110-2314-B-037-071National Science and Technology Council NSTC 111-2314-B-037-058
6 · The paper itself

Abstract

Neurotrophic receptor tyrosine kinase 3 (NTRK3) has pleiotropic functions: it acts not only as an oncogene in breast and gastric cancers but also as a dependence receptor in tumor suppressor genes in colon cancer and neuroblastomas. However, the role of NTRK3 in upper tract urothelial carcinoma (UTUC) is not well documented. This study investigated the association between NTRK3 expression and outcomes in UTUC patients and validated the results in tests on UTUC cell lines. A total of 118 UTUC cancer tissue samples were examined to evaluate the expression of NTRK3. Survival curves were generated using Kaplan-Meier estimates, and Cox regression models were used for investigating survival outcomes. Higher NTRK3 expression was correlated with worse progression-free survival, cancer-specific survival, and overall survival. Moreover, the results of an Ingenuity Pathway Analysis suggested that NTRK3 may interact with the PI3K-AKT-mTOR signaling pathway to promote cancer. NTRK3 downregulation in BFTC909 cells through shRNA reduced cellular migration, invasion, and activity in the AKT-mTOR pathway. Furthermore, the overexpression of NTRK3 in UM-UC-14 cells promoted AKT-mTOR pathway activity, cellular migration, and cell invasion. From these observations, we concluded that NTRK3 may contribute to aggressive behaviors in UTUC by facilitating cell migration and invasion through its interaction with the AKT-mTOR pathway and the expression of NTRK3 is a potential predictor of clinical outcomes in cases of UTUC.

Indexed as

Cell MovementReceptor, trkCUrologic NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMalePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesMTOR protein, humanNTRK3 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, trkCTOR Serine-Threonine KinasesAKT‐mTOR pathwayneurotrophic receptor tyrosine kinase 3 (NTRK3)prognosistropomyosin‐related kinase (TrK)upper tract urothelial carcinoma (UTUC)

Identifiers

PMID38593276
PMCPMC11895571
OpenAlexW4394596338

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.